To the Editor:

 {#ijlh13320-sec-0001}

In March 2020, the infection caused by SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus 2) was declared a pandemic by the World Health Organization. This global health emergency had in Spain one of its epicenters.

As the scientific community gained clinical experience about COVID‐19 (coronavirus disease 2019) and more and more clinical reports were published, an increased thrombotic risk was observed in patients infected with this novel virus. Subsequently, this hypothesis was confirmed with the performance of the first autopsies, being deep vein thrombosis and massive pulmonary embolisms common findings.

Several references exist in the literature to the possible relation between the presence of a lupus anticoagulant (LA) and the prothrombotic state experienced by these patients.[^1^](#ijlh13320-bib-0001){ref-type="ref"}, [^2^](#ijlh13320-bib-0002){ref-type="ref"}

In our center, we retrospectively analyzed 27 patients who had been tested for antiphospholipid antibodies between March 13th and April 26th of 2020, during their hospital admission due to COVID‐19 (confirmed by a positive RT‐PCR for SARS‐CoV‐2 in a nasopharyngeal swab). Informed consent was obtained, and no change in clinical practice was made according to the results. All of them were on prophylactic heparin, and the determinations were made 24 hours after the last dose. Their clinical and laboratory characteristics are described in Table [1](#ijlh13320-tbl-0001){ref-type="table"}. Patients receiving warfarin or direct oral anticoagulants were excluded.

###### 

Characteristics of the patients

  Characteristics                     Patients (n=27)                                   Reference range
  ----------------------------------- ------------------------------------------------- ----------------------
  Age (years)                         58 (20‐90)                                        
  Gender                                                                                
  Female                              55,6%                                             
  Male                                44,4%                                             
  Cardiovascular risk factors                                                           
  Hypertension                        37%                                               
  Dyslipidemia                        33%                                               
  Diabetes                            11%                                               
  Smoker                              14,8%                                             
  Obesidad (BMI \> 30 Kg/m2)          18,5%                                             
  Medical history                                                                       
  Autoimmune disease                  11.1% (3/27)                                      
  Cancer                              7% (2/27)                                         
  Laboratory findings                                                                   
  Hemoglobin                          13,6 (9,2‐16,2)                                   g/dL \[13.0‐16.8\]
  Platelets                           222.000 ( 108.000‐599.000)                        ×1000/µL \[140‐450\]
  Lymphocytes                         1100 (100‐3100)                                   ×1000/µL \[1.2‐4.0\]
  LDH                                 329 (190‐811)                                     U/L \[135‐225\]
  CRP                                 7,32 (0,04‐36,6)                                  mg/dL \[0.10‐0.50\]
  Ferritin                            1070 (137‐7459)                                   ng/mL \[30‐400\]
  Fibrinogen                          648 (373‐1412)                                    mg/dL \[200‐560\]
  IL‐6                                252 (0‐782)                                       pg/mL \[\<40\]
  D‐dimer                             2367 (223‐8138)                                   ng/mL \[\<500\]
  Prothrombin activity                83 (60‐115)                                       \% \[75‐140\]
  Prothrombin time                    12,8 (10,7‐16,5)                                  s \[9.7‐13.9\]
  aPTT                                TTPa: 32 (21‐48)                                  s \[26‐39\]
  Lupus anticoagulant                 22,2% (6/27)                                      
  Anticardiolipin antibodies          0% (0/27)                                         
  Anti‐B2 glycoprotein I antibodies   3,7% (1/27)                                       
  ICU                                                                                   
  Admission                           22,2% (6/27)                                      
  Median stay (days)                  25 (6‐30)                                         
  Thrombotic event                                                                      
  Arterial                            Lower extremities arterial ischemia 7,4% (2/27)   
  Venous                              Deep vein thrombosis 22,2% (6/27)                 
                                      Pulmonary embolism 37% (10/27)                    
                                      Stroke 7,4% (2/27)                                
  Death                               11,1% (3/27)                                      
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For the detection of lupus anticoagulant (LA), the dilute Russel viper venom test (dRVVT, HemosIL™, reagent: HemosIL dRVVT Screen/Confirm, Instrumentation Laboratory, Werfen) and the silica clotting time (SCT, HemosIL™, reagent: HemosIL Silica Clotting Time, Instrumentation Laboratory, Werfen) were used with screen/confirm reagents, while for the determination of anticardiolipin (aCL) antibodies (IgM and IgG) and anti‐beta‐2 glycoprotein I antibodies (IgA, IgM and IgG) a serological enzyme‐linked immunosorbent assay (ELISA) was performed (reagent: QUANTA aB2GPI Lite, INOVA Diagnostics).

A total of 6 patients (22,2%) were positive for LA and 1 (3.7%) for IgA anti‐beta‐2 glycoprotein I antibodies. No double antibody positivity was found.

A total of 15 patients (55,5%) had a thrombotic event from which only 3 had a positive antiphospholipid antibody determination (2 for LA, 1 for IgA anti‐beta‐2 glycoprotein I antibodies). From them, 13 patients had thrombotic risk factors such as hypertension, dyslipidemia, diabetes, obesity, smoking habit, or cancer.

A total of 6 patients (22,2%) required admission to an intensive care unit due to respiratory failure following an acute respiratory distress syndrome (ARDS), 5 of them experienced a thrombotic event, being pulmonary embolism the most frequent among them (56%). In 3/6 (50%), LA was positive. This last finding entails a higher percentage of patients with LA positivity among critical patients compared to the total number of patients (22,2% of LA positivity), as described by Helms J et al.[^1^](#ijlh13320-bib-0001){ref-type="ref"}

A total of three patients died of respiratory failure, they all suffered at least 1 thrombotic event (1 of them endured simultaneously a deep vein thrombosis, a pulmonary embolism, and an ischemic stroke), and only 1 had a confirmed LA.

Antiphospholipid antibodies can be temporarily detected during infectious episodes, and in this specific setting, they are not clearly related to an increased thrombotic risk. Moreover, given the possibility of LA false positives due to an elevated C‐reactive protein and its high affinity for phospholipids, this determination is not recommended in such episodes.[^2^](#ijlh13320-bib-0002){ref-type="ref"}

In accordance with Zhang et al,[^3^](#ijlh13320-bib-0003){ref-type="ref"} we do not consider the testing of LA cost‐effective when performed to every COVID‐19 patient, because of its high variability among them. In addition, LA positivity does not seem to predict thrombotic risk or have a clinical utility in deciding when to modify antithrombotic therapy, as mentioned by Harzallah et al,[^4^](#ijlh13320-bib-0004){ref-type="ref"} even though our LA positivity rate was lower (45% vs 22.2%), as it was for the remaining antiphospholipid antibodies (10% vs 3.7%).

Regarding the possible usefulness of a prolonged activated partial thromboplastin time (aPTT) (reagent used: SynthASil, Instrumentation Laboratory, Werfen) as a guide to test for the presence of antiphospholipid antibodies, just like Bowles et al[^5^](#ijlh13320-bib-0005){ref-type="ref"} and Connell et al[^6^](#ijlh13320-bib-0006){ref-type="ref"} describe, we did not find it useful, only 1 of our 27 patients had a prolonged aPTT and presence of LA, while the remaining patients with positive LA had no coagulation abnormalities.

We agree with Beyrouti R et al,[^7^](#ijlh13320-bib-0007){ref-type="ref"} considering a prolonged aPTT not a very sensitive test to predict the possible positivity of LA, because of the potential interference of other factors that can shorten (such as factor VIII) or prolong it (such as factor XII or C‐reactive protein).

In conclusion, according to our experience, LA determination may be unnecessary for COVID‐19 patients due to its high variability in acute infections and its lack of predictive capability of thrombotic risk, except in critical patients whose clinical situation is already an additional risk factor.

All SARS‐CoV‐2‐infected patients should receive antithrombotic prophylaxis regardless of the presence of LA due to their increased thrombotic risk as a consequence of multiple factors (hyperinflammation, platelet activation, and endothelial dysfunction) and its positivity should not change this practice.
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